Possmei is a leading Taiwan-based bubble tea supplier, providing high-quality ingredients and professional equipment to beverage businesses worldwide. Our product range includes tapioca pearls, fruit syrups, flavored powders, premium teas, toppings, aluminum cans, and complete shop equipment solutions.With branch offices in the USA and Germany, Possmei offers efficient global support, stable supply chains, and localized service for our international partners.We also offer RTD (Ready-to-Drink) beverages under our brand Popping Jacky, delivering convenient, innovative drink solutions that meet modern market trends.At Possmei, we are committed to quality, innovation, and helping our partners build successful beverage brands around the world. | Possmei specializes in the distribution of a wide range of bubble tea-related products and bubble tea RTD, which including tapioca pearls, fruit syrups, fruit mixed powder, teas, various toppings, and other essential equipment and machinery used in the preparation of bubble tea. There are four flavors of popping boba ready to drink : Strawberry and dragon fruit oolong tea, Lychee oolong tea , Peach oolong tea and Mango passion fruit green tea . Possmei’s products are widely used by bubble tea shops, restaurants, beverage shops, and even cafes. We have offices in both the USA and the EU, which provide nearby services.
Pop-Smile Asian Popcorn
We represent Asia Cuisine Culture by bringing Asia Flavored Popcorn to the world. Pop-Smile brand Popcorn and OEM Popcorn have been traveling over 40 countries and with 200 more Popcorn flavors. We are strongly audited by big Retail and Wholesale and contract with all global partners from Retails to HORECA. Taiwan Smile Food also owns a Popcorn Tourism Factory, the first and only in the world. With strong R&D, fulfillment of global certifications, Pop-Smile is your trustworthy and valuable snacks business partners. As we continue to expand internationally, we remain committed to quality, authenticity, and the joy of sharing Asian culinary culture with every customer. With Boba Culture Popcorn, we are not just offering a snack—we are delivering a cultural experience that bridges continents, celebrates creativity, and invites the world to taste Asia like never before. At Pop-Smile, we’re not just making popcorn—we’re sharing Asia’s story, one exciting flavor at a time.
PODAK CO., LTD
Podak is a professional manufacture of Heat Pump, providing HP solutions to international renowned enterprises.
Plustek Inc.
Plustek Inc., founded in 1986, has become the global imaging solution provider that designs, manufactures, and markets a comprehensive range of document scanners and intelligent process automation technologies. Our cutting-edge solution helps optimizes business workflow and shape organizations to grow their businesses.
PhytoHealth Corporation
PhytoHealth is an industry pioneer focusing on novel botanical drug development through a “disease-targeted research model”. The objective of the company is to innovate plant-based treatments to improve patients’ quality of life.
Pharmigene Inc
Established in 2005, Pharmigene Inc. is a leading biotechnology company specializing in pharmacogenomic testing. We hold exclusive global licenses from Academia Sinica for patents related to genetic testing for Warfarin and other critical medications such as Carbamazepine and Allopurinol. Leveraging these proprietary technologies, we have developed advanced diagnostic products and tools that have secured comprehensive technical patent certifications across numerous countries worldwide, including the USA, Europe, New Zealand, Australia, Japan, China, India, and Southeast Asia.Headquartered in Taiwan, Pharmigene operates a state-of-the-art R&D center and maintains stringent quality management systems. Our commitment to excellence is underscored by our certifications, including international ISO 13485, Taiwan QMS (GMP), and South Korea KGMP, ensuring the highest standards in medical device manufacturing and diagnostic solutions.
Pharmasaga Co. Ltd.
Pharmasaga Co. Ltd. (https://www.pharmasaga.com/en/index.aspx), is a drug discovery and development company. It aims to develop novel anti-diabetic small-molecule drugs that can treat and reverse diabetes. Pharamsaga pioneered to study function and mechanism of Pdia4, a master gene that controls β-cell pathogenesis and, in turn, diabetes. Using a rational drug design strategy, combining molecular docking, Pdia4 bioassay, and chemical synthesis, PS1, a Pdia4-based drug candidate, was developed for diabetes. This novel drug precisely targets diabetes and has the potential to become the world’s first curative treatment for diabetes. After receving IND approvals from the USFDA and Taiwanese FDA, PS1 is now on human trials for type 2 diabetes, followed by human trials for type 1 diabetes and pancreatic cancer. Preliminary data showed that PS1 had high safety and great efficacy in decreased blood glucose. Additionally, Orphan Drug Designation (ODD) of PS1 was applied to USFDA.
PharmaEssentia Corp
PharmaEssentia is working to redefine the potential of proven therapies to enhance the health and quality of life for patients living with hematologic diseases. Powered by world-class expertise and grounded in pioneering science, we are developing novel treatment solutions, beginning with therapies for myeloproliferative neoplasms (MPNs). Our flagship product, BESREMi, was approved by FDA in 2021 for all-comers polycythemia vera. | PharmaEssentia is working to redefine the potential of proven therapies to enhance the health and quality of life for patients living with hematologic diseases. Powered by world-class expertise and grounded in pioneering science, we are developing novel treatment solutions, beginning with therapies for myeloproliferative neoplasms (MPNs). We’re working to develop new hematology/oncology therapies by looking at a proven therapeutic concept with a fresh perspective. Drawing on our deep biopharmaceutical expertise, we’re aiming to transform the risk/benefit profiles of existing therapies. Our goal: to give physicians new therapeutic tools for early intervention—while giving new hope to patients with rare cancers. | PharmaEssentia Corporation (TWSE: 6446) headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. | PharmaEssentia Crop., headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator and the developer and owner of BESREMi® (ropeginterferon alfa-2b-njft). Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.